Outcomes of Cold Stored Saphenous Vein Allografts for Haemodialysis Vascular Access

Abstract

The aim of this study was to evaluate the outcome of cold stored saphenous vein allografts (CSVAs) for haemodialysis vascular access. A retrospective, two centre study was conducted between January 2016 and December 2020 of all patients who had CSVA placement for haemodialysis vascular access. Primary, primary assisted, and secondary patency were analysed, as well as procedural complications and re-interventions. A total of 109 patients (n = 55 women) with a mean age of 67.2 ± 13.6 years, with no options for creating an autogenous arteriovenous fistula, were included in the study. At 1 year, primary, primary assisted, and secondary patency were 38%, 59%, and 73%, respectively; and at 2 years they were 20%, 43%, and 55%, respectively. During a mean follow up period of 26 ± 18 months, five patients (4.6%) had an access infection, with no related death. During the follow up period, 32 patients (29.4%) died and 13 patients (11.9%) underwent a kidney transplant. None of these patients showed immunoconversion before transplantation. The cumulative incidence of adverse events by the Fine-Gray method was calculated. Considering competing risks (death and renal transplantation), 9% of patients lost their vascular access at 1 year and 18% at 2 years. Moreover, 57.8% patients had stenosis, mainly on the outflow (45.9%), and 49.5% had thrombosis. With a comparable patency rate associated with a low rate of infection, CSVA offers a potential alternative to expanded polytetrafluoroethylene grafts. This creates haemodialysis vascular access when the venous capital is exhausted in patients with reported risk factors for vascular access infection, i.e., insertion in the thigh, advance age, diabetes mellitus, immunocompromised state, obesity, or revision of an infected prosthetic graft.